Sudamed Pharma is a leading pharmaceutical company in the East African market, dedicated to providing better access to high-quality, affordable medication. With a vision to improve health outcomes, Sudamed Pharma mobilizes human and natural resources to produce generic medications and biosimilars that are accessible to Sudanese people at affordable prices.

The company aims to work with generic manufacturers in the UK and Europe, challenging the notion that imported medications are beyond the reach of limited budgets. Through a free-market approach, competition between manufacturers, and incentives for prescribers and pharmacists, Sudamed Pharma aims to make generic prices the lowest in the developed world.

By leveraging this approach, Sudan could have saved a significant amount in 2020, such as 30% of the budget spent on a commonly used Asthma inhaler, equivalent to 2.4 million Euros. Additionally, the cost of a single originator antidepressant in Sudan was 20 times higher than the average generic equivalent in the UK.

The founders, Osman Freigoun and Mousab Ameer Almamoun, have extensive experience in the pharmaceutical industry and a deep commitment to maximizing health outcomes while minimizing the overall cost of medicines. They believe that bio-equivalent, high-quality generic medicines are the most cost-effective treatment option.

Sudamed Pharma aims to play a leading role in making these medicines available to Sudanese citizens at affordable prices, contributing to the improvement of healthcare and well-being in Sudan.